Development of a Noninvasive Method of Evaluation of Pulmonary Inflammation in the Condensates of Exhaled Air

Development of a Noninvasive Method of Evaluation of the Pulmonary Inflammation in the Condensates of Exhaled Air

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00356629

Enrollment

100

Registered

2006-07-26

Start date

2006-07-31

Completion date

2008-07-31

Last updated

2008-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma, Bronchopulmonary Ignition, Condensate of Exhaled Air, Mucoviscidosis

Keywords

bronchopulmonary ignition, condensate of exhaled air, Mucoviscidosis, Asthma

Brief summary

The aim of the study is identify biological parameters reflecting proteolytic activity in the exhaled condenstaes which might be useful to follow up pulmonary inflammation in various conditions including cystic fibrosis, COPD, asthma, tobacco exposure. Three proteases will be analyzed, i.e. elastase, proteinase 3 and cathepsin G. Results in the condensates will be compared to those obtained in sputum.

Detailed description

5 groups of 20 individuals each: group 1 CF, group 2 COPD, group 3 asthma, group 4 tobacco exposure, group 5 control subjects. Collection of exhaled condensates in all subjects and of sputum in subjects belonging to groups 1 and 2. Clinical examination and PFTs in all patients.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Subjects suffering from CF, COPD, asthma and tobacco exposure (groups 1 to 4) and controls (group 5) * aged more or equal to 18 * stable disease * able to perform PFTs * informed consent signed * affiliated to french social insurance

Exclusion criteria

* acute exacerbation of the disease during the last 2 weeks * IV or oral steroids or antibiotics during the last 2 weeks * hospitalization during the last 2 weeks * colonization by S aureus methicillin resistant and/or Burkholderia cepacia

Countries

France

Outcome results